GTC Biotherapeutics (fka GTCB)

[shears]

I like to keep it simple. There's a 95% likelihood or greater that if Atryn doesn't cause symptomatic DVT then it will be found non-inferior. It's a lot lower bar than trying to show superiority. It's like being a midget in a limbo contest whose goal is not to lose. I like the odds and I've got my money on the midget. Why shouldn't it work? I'll bet GTCB is negotiating their pants off trying to cut a good deal with a much bigger pharma and attempting to avoid getting steamrolled in the process. Its called dancing with elephants without getting squished. The biggest risk I see is a partnership deal that isn't as sweet as investors hope for, but at least insures survival. The current share price creates doubts. Fortune favors the brave little people.